Skip to main content

Table 1 Patient demographic and baseline clinical characteristics (including all on- and off-drug data)

From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

  TTP488 20 mg/day TTP488 5 mg/day Placebo
  (n = 135) (n = 131) (n = 133)
Age (years) 73.0 ± 9.0 73.6 ± 8.8 72.2 ± 9.6
Sex (% women) 61 53 57
Race    
  White 128 120 125
Education (years) 15.0 ± 3.0 14.8 ± 2.8 15.3 ± 2.8
MMSE 19.9 ± 3.6 20.8 ± 3.5 20.5 ± 3.4
  Mild (MMSE ≥20), n(%) 71 (53%) 84 (64%) 81 (61%)
  Moderate (MMSE < 20), n(%) 64 (47%) 47 (36%) 51 (39%)
ADAS-cog 24.9 ± 9.7 24.4 ± 9.8 24.1 ± 9.6
CDR-sb 5.7 ± 2.9 5.6 ± 2.7 6.0 ± 2.8
ADCS-ADL 61.3 ± 12.9 61.4 ± 12.3 59.9 ± 12.8
NPI 7.9 ± 10.5 7.7 ± 10.3 8.6 ± 10.4
APOE e4+status, n (%) 62 65 74
 E2/E3 3 (2.3%) 5 (4.2%) 1 (0.9%)
 E2/E4 7 (5.4%) 2 (1.7%) 2 (1.7%)
 E3/E3 46 (35.7%) 36 (30.5%) 30 (25.6%)
 E3/E4 47 (36.4%) 53 (44.9%) 59 (50.4%)
 E4/E4 26 (20.2%) 20 (16.9%) 25 (21.4%)
Unknown/Missing 6 15 16
AchEI use, n(%) 134 (99%) 129 (98%) 132 (100%)
Memantine use, n (%) 92 (68%) 87 (66%) 96 (73%)
  1. Unless otherwise indicated, data reported as mean ± SD.
  2. MMSE = Mini-Mental State Examination, ADAS-cog = Alzheimer’s Disease Assessment Scale cognitive. CDR-sb = Clinical Dementia Rating sum of boxes, ADCS-ADL = Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale, NPI = Neuropsychiatric Inventory, APOE e4 = Apolipoprotein E e4 allele, AchEI = acetylcholinesterase inhibitor.